Tag : NON-SMALL CELL LUNG CANCER
The 7-year CROWN update showed lorlatinib providing durable PFS and sustained intracranial disease control vs. crizotinib in advanced ALK+ NSCLC. A consistent long-term safety profile and sustained benefit across patient subgroups further support lorlatinib as the preferred first-line standard of care.
In the phase 3 FLAURA2 study, osimertinib + platinum-pemetrexed demonstrated statistically significant improvements in progression-free survival and overall survival vs. osimertinib monotherapy in epidermal growth factor receptor-mutated advanced non-small cell lung cancer, achieving a median OS of 47.5 months.
The landscape of early-stage non-small cell lung cancer is undergoing a rapid transformation. Once defined by the modest survival gains of adjuvant chemotherapy, treatment strategies now extend to immunotherapy and targeted therapies in both adjuvant and neoadjuvant settings.
Lorlatinib is a brain-penetrant third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) which covers a broader ALK resistance profile than second-generation ALK TKIs. It has previously demonstrated improved PFS and IC activity compared to crizotinib in treatment-naïve patients with advanced ALK+ NSCLC in the ongoing randomized phase 3 CROWN study.
